Bundibugyo Ebola crosses into Kenya and Nigeria as a vaccine trial begins in Congo

The Bundibugyo virus outbreak that has run in the Democratic Republic of the Congo since May has now been exported across two international borders. In its Disease Outbreak News of 23 October, WHO reports that cases have been confirmed in five countries since the outbreak was declared on 15 May 2026 — the DRC, Uganda, France, and now Kenya and Nigeria [s1]. The two newest are the reason the notice reads as an escalation rather than another fortnightly tally.

Kenya and Nigeria

Kenya has recorded its first cluster. As of 20 October 2026, a total of nine cases, including one death, had been reported there [s1]. Of the eight secondary cases, four are family members and four are health and care workers — the pattern of transmission that most alarms outbreak responders, because infected clinicians both signal a breach in infection control and seed onward spread [s1]. Kenya reported its first imported case on 6 October, and as of 20 October 135 contacts had been traced and quarantined [s1].

Nigeria's exposure is so far a single case. On 20 October 2026, the country reported one laboratory-confirmed imported case of Bundibugyo virus disease in the Federal Capital Territory, Abuja [s1]. Of the 44 contacts identified by that date, all were being monitored [s1]. One imported case is not an outbreak, but in a city the size of Abuja it is the kind of event that decides whether there is one, and the speed with which those 44 contacts are followed will largely settle it.

The outbreak at source

Inside the DRC the numbers remain severe. As of 20 October, cumulative confirmed cases had reached 9,704, including 4,687 deaths and 2,595 recoveries, across 66 health zones in eight provinces [s1]. The overall crude case fatality ratio stands at 48.3% — close to where it has sat for months, and a reminder that this is a species of ebolavirus for which no vaccine is licensed and against which roughly half of confirmed patients die [s1].

The burden is heavily concentrated. Ituri province accounts for 7,040 confirmed cases and 3,271 deaths; Nord Kivu for 2,146 cases and 1,199 deaths; Haut-Uélé for 421 cases and 183 deaths; and Tshopo for 76 cases and 27 deaths, with the remaining provinces reporting smaller numbers [s1]. The tracing load is correspondingly large: 30,130 contacts were under follow-up across six provinces, of whom 24,017 — a follow-up rate of 79.7% — were seen in the previous 24 hours, below the 95.0% threshold WHO sets as adequate [s1]. A gap of that size is where undetected chains of transmission hide.

A vaccine trial, at last

The notice carries one piece of forward movement. On 23 October, the TUMAINI vaccine trial was launched, with its first participants enrolled in Bunia, the capital of Ituri and the epicentre of the outbreak [s1]. The DON does not report an enrolment count or results, and a trial that began the day the notice published can offer no efficacy signal yet. It matters because the absence of a proven vaccine against Bundibugyo virus — distinct from the Zaire ebolavirus that licensed vaccines target — has been the defining weakness of this response from the start. A trial launching is not protection, but it is the first step toward it.

What to watch

WHO's most recent formal risk assessment, dated 14 August, rated the risk very high for the DRC, high for countries sharing a land border, and low for the rest of the African region and globally; the agency says that assessment is now being revised [s1]. The Kenyan and Nigerian cases are exactly the development a revision would weigh. Nigeria does not border the DRC, so an imported case there tests the assumption that risk falls away with distance.

The questions for the coming weeks are concrete. Whether Kenya's nine cases stay contained or generate a second generation of infections among the traced contacts; whether Nigeria's single case remains single; whether the DRC's follow-up rate recovers toward the 95% mark; and whether the TUMAINI trial can enrol fast enough, in an active outbreak, to produce an answer while it still matters. None of those will be settled by the next notice, but each is now the thing to read it for.